局部晚期宫颈癌放化疗及影像引导自适应近距离放疗后的远处转移
基于EMBRACE I前瞻性队列中1318例局部晚期宫颈癌患者,分析放化疗联合MR影像引导自适应近距离放疗后远处转移的模式与风险。中位随访52个月,5年远处转移累积发生率为14%,肺、纵隔淋巴结和骨为常见转移部位;非鳞癌、诊断时淋巴结转移及近距离放疗靶区体积大是远处转移的危险因素,化疗少于4周期者远处转移风险显著升高。
要点
- 5年远处转移累积发生率为14%,肺、纵隔淋巴结、骨最常见。
- 非鳞癌、盆腔或腹主动脉旁淋巴结转移、近距离放疗靶区体积大增加远处转移风险。
- 化疗少于4周期者远处转移风险显著升高(HR 1.52)。
核心结论
- 局部晚期宫颈癌患者远处转移负担显著,肺、远处淋巴结和骨为最常见部位。
- 非鳞癌组织学、诊断时淋巴结受累及近距离放疗时靶区体积大是识别高危患者的关键考虑因素。
- 研究结果提示需要制定针对性策略以减少该人群的远处转移。
研究设计与样本
- 纳入1416例活检证实的宫颈癌患者(FIGO2009分期IB-IVA或IVB局限于L1/L2间隙以下腹主动脉旁淋巴结),最终分析1318例,中位年龄49岁,中位随访52个月。
- 治疗包括外照射放疗(45-50.4 Gy)、每周顺铂(40 mg/m²、30 mg/m²或暂停)及影像引导自适应近距离放疗。
- 远处转移定义为排除腹主动脉旁淋巴结的盆腔外复发。
主要发现
- 5年远处转移累积发生率为14%,最常见转移部位为肺(26%)、纵隔淋巴结(15%)和骨(10%)。
- 非鳞癌组织学与远处转移风险升高相关(HR 1.89;95% CI 1.30-2.75)。
- 诊断时盆腔淋巴结转移(HR 1.56;95% CI 1.07-2.26)和腹主动脉旁淋巴结转移(HR 3.15;95% CI 1.93-5.16)与远处转移风险升高相关。
- 近距离放疗时靶区体积大与远处转移风险升高相关(HR 1.93;95% CI 1.21-3.08)。
- 接受少于4周期化疗的患者远处转移风险显著更高(HR 1.52;95% CI 1.08-2.13)。
关键数值与推荐
- 远处转移定义为排除腹主动脉旁淋巴结的盆腔外复发。
- 外照射放疗剂量为45-50.4 Gy,每周顺铂剂量为40 mg/m²、30 mg/m²或暂停。
- 远处转移风险因素包括非鳞癌组织学(HR 1.89;95% CI 1.30-2.75)、盆腔淋巴结转移(HR 1.56;95% CI 1.07-2.26)、腹主动脉旁淋巴结转移(HR 3.15;95% CI 1.93-5.16)、近距离放疗靶区体积大(HR 1.93;95% CI 1.21-3.08)及化疗少于4周期(HR 1.52;95% CI 1.08-2.13)。
临床怎么用
- 对于非鳞癌、诊断时淋巴结转移或近距离放疗靶区体积大的局部晚期宫颈癌患者,应视为远处转移高危人群。
- 应关注化疗周期数,少于4周期与远处转移风险升高相关。
- 随访中需重点关注肺、纵隔淋巴结和骨等常见远处转移部位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to assess patterns and risks of distant metastasis (DM) in patients with cervical cancer treated with chemoradiation therapy and MR-image guided adaptive brachytherapy (IGABT) and to explore a potential dose-effect relationship of concomitant cisplatin. METHODS AND MATERIALS: Data were derived from EMBRACE I, an international, prospective, and multicenter cohort study conducted at 24 centers across Europe, Asia, and North America from July 30, 2008, to December 29, 2015. The study included 1416 patients with biopsy-confirmed cervical cancer (International Federation of Gynecology and Obstetrics [FIGO2009] stage IB-IVA or stage IVB limited to paraaortic lymph nodes below the L1/L2 interspace). Treatment involved external beam radiation therapy (45-50.4 Gy), weekly cisplatin (40 mg/m², 30 mg/m², or paused), and IGABT. DM was defined as extra-pelvic recurrence excluding paraaortic nodes. RESULTS: The analysis included 1318 patients with a median age of 49 years and a median follow-up of 52 months. The 5-year cumulative incidence of DM was 14%, with the lungs (26%), mediastinal lymph nodes (15%), and bones (10%) identified as the most common metastatic sites. Key risk factors for DM included nonsquamous histology (HR, 1.89; 95% CI, 1.30-2.75), nodal involvement at diagnosis (pelvic-only nodes: HR, 1.56; 95% CI, 1.07-2.26; paraaortic nodes: HR, 3.15; 95% CI, 1.93-5.16), and large target volume at brachytherapy (HR, 1.93; 95% CI, 1.21-3.08). Patients receiving fewer than 4 cycles of chemotherapy demonstrated a significantly higher risk of DM (HR, 1.52; 95% CI, 1.08-2.13). CONCLUSION: DM is a substantial burden in patients with locally advanced cervical cancer, with the lungs, distant lymph nodes, and bones being the most frequent sites. Risk factors such as nonsquamous histology, nodal involvement, and large target volumes at brachytherapy are critical considerations for identifying high-risk patients in future studies. These findings highlight the need for tailored strategies to mitigate DM in this patient population.
引用
- Knoth J, Nout RA, Pötter R, et al. Distant Metastasis After Chemoradiation and Image Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 40354949. doi:10.1016/j.ijrobp.2025.04.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。